Author
Listed:
- Mary Premenko-Lanier
(Emory Vaccine Center and Department of Microbiology and Immunology
Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA)
- Nelson B. Moseley
(Emory Vaccine Center and Department of Microbiology and Immunology
Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA)
- Sarah T. Pruett
(Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA)
- Pablo A. Romagnoli
(Emory Vaccine Center and Department of Microbiology and Immunology
Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA)
- John D. Altman
(Emory Vaccine Center and Department of Microbiology and Immunology
Yerkes National Primate Research Center and Emory University School of Medicine, 954 Gatewood Road, Atlanta, Georgia 30329, USA)
Abstract
FTY720: a dual-role drug? FTY720 (fingolimod) is a drug that has been tested in human clinical trials for treating multiple sclerosis and preventing kidney transplant rejection. It is regarded as a novel class of immunosuppressive agent that works by sequestering lymphocytes in lymph nodes, keeping them away from sites of pathology. Premenko-Lanier et al. now report a new and counter-intuitive use of FTY720: a three-day, low-dose course of FTY720 can both prevent establishment of a chronic lymphocytic choriomeningitis infection in mice, and cure an established chronic infection. Clearance of the virus is associated with an augmented immune response. The next question is, is this approach translatable to human chronic infections?
Suggested Citation
Mary Premenko-Lanier & Nelson B. Moseley & Sarah T. Pruett & Pablo A. Romagnoli & John D. Altman, 2008.
"Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection,"
Nature, Nature, vol. 454(7206), pages 894-898, August.
Handle:
RePEc:nat:nature:v:454:y:2008:i:7206:d:10.1038_nature07199
DOI: 10.1038/nature07199
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:454:y:2008:i:7206:d:10.1038_nature07199. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.